KYORIN Expands Performance-Linked Stock Compensation Plan to Corporate Officers

KYORIN Pharmaceutical Co.,Ltd. ( (JP:4569) ) has shared an announcement.

KYORIN Pharmaceutical has approved a partial revision of its performance-linked stock compensation plan, which was originally introduced in 2016 and updated in 2023. The key change is the inclusion of corporate officers under delegation agreements, alongside directors, as eligible participants in the existing Board Benefit Trust-based scheme.

Under the revised plan, a trust funded by the company acquires KYORIN shares on the market and allocates them to directors and now corporate officers based on position and achievement of performance targets. The trust will not exercise voting rights on the held shares, and beneficiaries may receive a mix of stock and cash, aligning management compensation more directly with company performance and shareholder interests.

More about KYORIN Pharmaceutical Co.,Ltd.

KYORIN Pharmaceutical Co., Ltd. is a Japan-based drugmaker listed on the Tokyo Stock Exchange Prime Market under security code 4569. The company focuses on ethical pharmaceuticals and healthcare-related products, operating in a competitive domestic and global pharmaceutical industry where executive incentives are closely tied to long-term performance and shareholder value.

Average Trading Volume: 104,171

Technical Sentiment Signal: Buy

Current Market Cap: Yen81.59B

For an in-depth examination of 4569 stock, go to TipRanks’ Overview page.